QI
CBAY

QS Investors’s Cymabay Therapeutics CBAY Stock Holding History

QS Investors’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$399K Hold
91,400
– – ﹤0.01% 832
2021
Q1 		$415K Buy
91,400
+36,200
+66% +$195K ﹤0.01% 863
2020
Q4 		$317K Buy
+55,200
New +$418K ﹤0.01% 969

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

QS Investors's CBAY Position: Q2 2021 in Review

QS Investors held its Cymabay Therapeutics (CBAY) position steady in Q2 2021 at 91,400 shares worth $399K. The position accounts for ﹤0.01% of the portfolio, ranked #832.

QS Investors first reported a position in CBAY in Q4 2020 and has held it in 3 quarters since. The position peaked at $415K in Q1 2021. 113 funds tracked by Wall St. Rank hold CBAY as of Q2 2021.

  • QS Investors held 91,400 shares of Cymabay Therapeutics worth $399K as of Q2 2021.
  • QS Investors left its Cymabay Therapeutics share count unchanged in Q2 2021.
  • Cymabay Therapeutics made up ﹤0.01% of QS Investors's portfolio in Q2 2021, its #832 holding.
  • QS Investors first reported a position in Cymabay Therapeutics in Q4 2020 and has held it in 3 quarters since.
  • QS Investors's Cymabay Therapeutics position peaked at $415K in Q1 2021.
  • 113 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.